PEG-Intron

DRUG7 trials

Sponsors

Merck Sharp & Dohme LLC, M.D. Anderson Cancer Center, Wyeth is now a wholly owned subsidiary of Pfizer, University of Pittsburgh

Conditions

AIDSHIV InfectionsHepatitis CLeukemia, Myeloid, Philadelphia-PositiveMelanomaPlexiform Neurofibroma

Phase 1

High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2)

CompletedNCT00457418

Merck Sharp & Dohme LLCMelanoma

Start: 2007-02-20End: 2012-07-11Updated: 2017-06-07

Phase 2

PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron

TerminatedNCT00037882

M.D. Anderson Cancer CenterLeukemia, Myeloid, Philadelphia-Positive

Start: 2001-02-28End: 2003-12-03Updated: 2018-11-01

A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects

CompletedNCT00367887

Wyeth is now a wholly owned subsidiary of PfizerHepatitis C

Start: 2006-10-31End: 2008-07-31Updated: 2013-02-11

Study of PEG-Intron for Plexiform Neurofibromas

CompletedNCT00396019

University of PittsburghPlexiform Neurofibroma

Start: 2006-12-31End: 2014-04-30Updated: 2017-11-06

Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016)

CompletedNCT03537274

Merck Sharp & Dohme LLCHepatitis C

Start: 1997-08-05End: 1999-07-23Updated: 2019-04-09

SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)

TerminatedNCT03552549

Merck Sharp & Dohme LLCMelanoma

Start: 1998-08-05End: 2001-02-19Updated: 2019-07-24

Phase 3

Phase III PEG-Intron in HIV-infected Patients (Study P00738)

CompletedNCT00035360

Merck Sharp & Dohme LLCAIDS, HIV Infections

Start: 2002-03-31End: 2003-10-31Updated: 2017-03-10